These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 19272496)
1. Profile of the progesterone derivative chlormadinone acetate - pharmocodynamic properties and therapeutic applications. Druckmann R Contraception; 2009 Apr; 79(4):272-81. PubMed ID: 19272496 [TBL] [Abstract][Full Text] [Related]
2. Chlormadinone acetate (CMA) in oral contraception--a new opportunity. Bouchard P Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():7-11. PubMed ID: 16356876 [TBL] [Abstract][Full Text] [Related]
3. At 10 years of chlormadinone use in Latin America: a review. Barriga P P; Ambrosi Penazzo N; Franco Finotti M; Celis AA; Cerdas O; Chávez JA; Cuitiño LA; Fernandes CE; Plata MA; Tirán-Saucedo J; Vanhauwaert PS Gynecol Endocrinol; 2016 Jul; 32(7):517-20. PubMed ID: 27113551 [TBL] [Abstract][Full Text] [Related]
4. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Schramm G; Heckes B Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175 [TBL] [Abstract][Full Text] [Related]
5. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Plewig G; Cunliffe WJ; Binder N; Höschen K Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212 [TBL] [Abstract][Full Text] [Related]
7. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors. Schneider J; Kneip C; Jahnel U Pharmacology; 2009; 84(2):74-81. PubMed ID: 19590256 [TBL] [Abstract][Full Text] [Related]
8. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles. Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230 [TBL] [Abstract][Full Text] [Related]
9. [The antigonadrotropic activity of chlormadinone acetate in reproductive women]. Chassard D; Schatz B Gynecol Obstet Fertil; 2005; 33(1-2):29-34. PubMed ID: 15752663 [TBL] [Abstract][Full Text] [Related]
10. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea. Grandi G; Napolitano A; Xholli A; Tirelli A; Di Carlo C; Cagnacci A Gynecol Endocrinol; 2015 Oct; 31(10):774-8. PubMed ID: 26291811 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study. Zahradnik HP; Hanjalic-Beck A Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849 [TBL] [Abstract][Full Text] [Related]
12. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Winkler UH; Sudik R Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. Terlinden R; Uragg H; Göhler K; Kneip C Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418 [TBL] [Abstract][Full Text] [Related]
14. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Worret I; Arp W; Zahradnik HP; Andreas JO; Binder N Dermatology; 2001; 203(1):38-44. PubMed ID: 11549798 [TBL] [Abstract][Full Text] [Related]
15. Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content. Pluchino N; Lenzi E; Merlini S; Giannini A; Cubeddu A; Casarosa E; Begliuomini S; Luisi M; Cela V; Genazzani AR Contraception; 2009 Jul; 80(1):53-62. PubMed ID: 19501216 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro. Wiedemann C; Nägele U; Schramm G; Berking C Contraception; 2009 Sep; 80(3):292-8. PubMed ID: 19698824 [TBL] [Abstract][Full Text] [Related]
17. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Cagnacci A; Ferrari S; Tirelli A; Zanin R; Volpe A Contraception; 2009 Feb; 79(2):111-6. PubMed ID: 19135567 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog. Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095 [TBL] [Abstract][Full Text] [Related]
19. Effects of antiandrogenic progestins, chlormadinone and cyproterone acetate, and the estrogen 17α-ethinylestradiol (EE2), and their mixtures: Transactivation with human and rainbowfish hormone receptors and transcriptional effects in zebrafish (Danio rerio) eleuthero-embryos. Siegenthaler PF; Bain P; Riva F; Fent K Aquat Toxicol; 2017 Jan; 182():142-162. PubMed ID: 27907851 [TBL] [Abstract][Full Text] [Related]
20. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice. Pushparajah DS; Röhm P; Höschen K; Albers D; Nowack C Clin Drug Investig; 2011; 31(2):121-34. PubMed ID: 21155614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]